Derma Sciences Launches Medihoney Product in US

Derma Sciences DSCI, a medical device and pharmaceutical company focused on advanced wound care, today announced the U.S. launch and first commercial sales of MEDIHONEY® HCS (Hydrogel Colloidal Sheet), the latest in the MEDIHONEY line of advanced wound care products. MEDIHONEY® HCS is a patented dressing comprising a combination of the Company's MEDIHONEY® and XTRASORB® HCS dressings. The product will be available for the treatment of first- and second-degree burns, in addition to various chronic and acute wounds. MEDIHONEY® HCS will be highlighted at the Symposium on Advanced Wound Care (SAWC) Meeting in Baltimore September 12^th-14^th. Derma Sciences will be highlighting the product's two mechanisms of action, high osmoloarity and low pH, at booth #1316. Also being exhibited is the product's ability, because of the Super Absorbent Polymer technology, to help modulate MMPs from the wound environment. MMPs are protease enzymes that cause delayed healing. This combination dressing will be able to handle up to 2.5 times the amount of fluid of market-leading hydrocolloids, while also providing a moist environment for dry wounds.